GFAP
Reactivity: Human
WB, IHC, IF
Host: Rabbit
Monoclonal
unconjugated
Application Notes
K39 reacts exclusively with glial fibrillary acidic protein which is present in astrocytes in the central nervous system and Schwann cells. K39 is suitable for immunoblotting and immunohistochemistry on frozen and paraffin-embedded tissues. Optimal antibody dilution should be determined by titration, recommended range is 1:100 - 1:200 for immunohistochemistry with avidin-biotinylated horseradish peroxidase complex (ABC) as detection reagent, and 1:100 - 1:1000 for immunoblotting applications.
Restrictions
For Research Use only
Format
Liquid
Storage
4 °C
Herpers, Ramaekers, Aldeweireldt, Moesker, Slooff: "Co-expression of glial fibrillary acidic protein- and vimentin-type intermediate filaments in human astrocytomas." in: Acta neuropathologica, Vol. 70, Issue 3-4, pp. 333-9, (1986) (PubMed).
Ramaekers, Puts, Moesker, Kant, Huysmans, Haag, Jap, Herman, Vooijs: "Antibodies to intermediate filament proteins in the immunohistochemical identification of human tumours: an overview." in: The Histochemical journal, Vol. 15, Issue 7, pp. 691-713, (1983) (PubMed).
Target
GFAP
(Glial Fibrillary Acidic Protein (GFAP))
Alternative Name
Glial fibrillary acidic protein / GFAP (GFAP Products)
GFAP (55 kD) is selectively located in astrocytes and represents the major constituent of astrocytic intermediate filaments. GFAP expression levels are highly variable during development of the central nervous system. In adults, GFAP levels increase as a result of the proliferation of astrocytes that occurs in a response to a variety of physical, chemical and etiological insults, including Alzheimer€™s disease, epilepsy and multiple sclerosis. In the peripheral nervous system GFAP is expressed by Schwann cells. Upon differentiation, myelin forming Schwann cells down-regulate GFAP, whereas in non-myelin forming Schwann cells GFAP persists into adulthood.